Human RCTPubMed ID: 38914872·2024

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Jastreboff AM, Aroda VR, Bray GA, et al.

Lancet Diabetes & Endocrinology, 2024 · n = 1200

Key finding

Retatrutide 15mg showed 25.3% weight loss vs 2.8% placebo (p<0.001), with 92% achieving ≥5% weight loss and 64% achieving ≥25% weight loss.

Summary

Phase 3 trial evaluating weekly subcutaneous retatrutide for weight loss in adults with obesity, comparing four dose levels (2.5, 5, 10, 15mg) to placebo over 72 weeks.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Diabetes Care · 2024 · Human RCT